Core Viewpoint - Four Ring Pharmaceutical (00460) experienced a stock increase of over 5%, reaching 1.42 HKD, following the approval of a new indication for its innovative drug, Pyrotinib (brand name: XuanYueNing), for the first-line treatment of HR+/HER2- advanced breast cancer in China [1] Group 1 - The company announced that its subsidiary, XuanZhu Biotechnology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the supplemental new drug application (sNDA) of Pyrotinib [1] - This approval marks the third indication for Pyrotinib in China, following its previous approvals for combination therapy with Fulvestrant and monotherapy [1] - Pyrotinib is now the first and only drug in China to cover the entire treatment course for HR+/HER2- advanced breast cancer across first-line, second-line, and later lines of therapy, significantly expanding patient coverage and enhancing clinical value [1]
四环医药午前涨超5% 轩悦宁 第三个适应症上市申请获NMPA批准